MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.
This is not a financial advice!
Upcoming catalysts 03/08/2024 and 12/31/2024
Lots of block buys recently - as it seems someone knows something
We need to stay in a bullish overal sentiment of the market. If we see a corretion, this play might doesn't work.
Keep an eye on 4.8 / 5.6 / 6.3 levels, needs to get broken for a further upmove. You can take partial profits at these levels if u want to lock in gains.
SL under 4.3 (very tight)
TPs approx. 7.0 (if data on 03/08 will be good)
Most info on the chart.
Trade carefully!
This is not a financial advice!
Upcoming catalysts 03/08/2024 and 12/31/2024
Lots of block buys recently - as it seems someone knows something
We need to stay in a bullish overal sentiment of the market. If we see a corretion, this play might doesn't work.
Keep an eye on 4.8 / 5.6 / 6.3 levels, needs to get broken for a further upmove. You can take partial profits at these levels if u want to lock in gains.
SL under 4.3 (very tight)
TPs approx. 7.0 (if data on 03/08 will be good)
Most info on the chart.
Trade carefully!
Comment:
Friday March 15, 2024
MNKD
Block Trade: MNKD 1.1M @ $4.47
MNKD
Block Trade: MNKD 1.1M @ $4.47
Block Trade: MNKD 1.6M @ $4.97 at the ask
MNKD
Block Trade: MNKD 532,300 @ $4.94 at the ask